Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth

Hiromi I. Wettersten, Yosef Landesman, Sharon Friedlander, Sharon Shacham, Michael Kauffman, Robert H Weiss

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Despite the advent of FDA-approved therapeutics to a limited number of available targets (kinases and mTOR), PFS of kidney cancer (RCC) has been extended only one to two years due to the development of drug resistance. Here, we evaluate a novel therapeutic for RCC which targets the exportin-1 (XPO1) inhibitor. Materials and Methods: RCC cells were treated with the orally available XPO1 inhibitor, KPT-330, and cell viability and Annexin V (apoptosis) assays, and cell cycle analyses were performed to evaluate the efficacy of KPT-330 in two RCC cell lines. Immunoblotting and immunofluorescence analysis were performed to validate mechanisms of XPO1 inhibition. The efficacy and on-target effects of KPT-330 were further analyzed in vivo in RCC xenograft mice, and KPT-330-resistant cells were established to evaluate potential mechanisms of KPT-330 resistance. Results: KPT-330 attenuated RCC viability through growth inhibition and apoptosis induction both in vitro and in vivo, a process in which increased nuclear localization of p21 by XPO1 inhibition played a major role. In addition, KPT-330 resistant cells remained sensitive to the currently approved for RCC multi-kinase inhibitors (sunitinib, sorafenib) and mTOR inhibitors (everolimus, temsirolimus), suggesting that these targeted therapeutics would remain useful as second line therapeutics following KPT-330 treatment. Conclusion: The orally-available XPO1 inhibitor, KPT-330, represents a novel target forRCC whose in vivo efficacy approaches that of sunitinib. In addition, cells resistant to KPT-330 retain their ability to respond to available RCC therapeutics suggesting a novel approach for treatment in KPT-330-naïve as well as -resistant RCC patients.

Original languageEnglish (US)
Article numbere113867
JournalPLoS One
Volume9
Issue number12
DOIs
StatePublished - Dec 2 2014

Fingerprint

kidney neoplasms
Kidney Neoplasms
therapeutics
Growth
phosphotransferases (kinases)
apoptosis
cells
drug resistance
immunoblotting
Cells
growth retardation
fluorescent antibody technique
cell viability
cell cycle
Therapeutics
cell lines
KPT-330
exportin 1 protein
viability
Phosphotransferases

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Wettersten, H. I., Landesman, Y., Friedlander, S., Shacham, S., Kauffman, M., & Weiss, R. H. (2014). Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS One, 9(12), [e113867]. https://doi.org/10.1371/journal.pone.0113867

Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. / Wettersten, Hiromi I.; Landesman, Yosef; Friedlander, Sharon; Shacham, Sharon; Kauffman, Michael; Weiss, Robert H.

In: PLoS One, Vol. 9, No. 12, e113867, 02.12.2014.

Research output: Contribution to journalArticle

Wettersten, HI, Landesman, Y, Friedlander, S, Shacham, S, Kauffman, M & Weiss, RH 2014, 'Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth', PLoS One, vol. 9, no. 12, e113867. https://doi.org/10.1371/journal.pone.0113867
Wettersten, Hiromi I. ; Landesman, Yosef ; Friedlander, Sharon ; Shacham, Sharon ; Kauffman, Michael ; Weiss, Robert H. / Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. In: PLoS One. 2014 ; Vol. 9, No. 12.
@article{32a9f137e165428ab4a10c458edf6f5d,
title = "Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth",
abstract = "Purpose: Despite the advent of FDA-approved therapeutics to a limited number of available targets (kinases and mTOR), PFS of kidney cancer (RCC) has been extended only one to two years due to the development of drug resistance. Here, we evaluate a novel therapeutic for RCC which targets the exportin-1 (XPO1) inhibitor. Materials and Methods: RCC cells were treated with the orally available XPO1 inhibitor, KPT-330, and cell viability and Annexin V (apoptosis) assays, and cell cycle analyses were performed to evaluate the efficacy of KPT-330 in two RCC cell lines. Immunoblotting and immunofluorescence analysis were performed to validate mechanisms of XPO1 inhibition. The efficacy and on-target effects of KPT-330 were further analyzed in vivo in RCC xenograft mice, and KPT-330-resistant cells were established to evaluate potential mechanisms of KPT-330 resistance. Results: KPT-330 attenuated RCC viability through growth inhibition and apoptosis induction both in vitro and in vivo, a process in which increased nuclear localization of p21 by XPO1 inhibition played a major role. In addition, KPT-330 resistant cells remained sensitive to the currently approved for RCC multi-kinase inhibitors (sunitinib, sorafenib) and mTOR inhibitors (everolimus, temsirolimus), suggesting that these targeted therapeutics would remain useful as second line therapeutics following KPT-330 treatment. Conclusion: The orally-available XPO1 inhibitor, KPT-330, represents a novel target forRCC whose in vivo efficacy approaches that of sunitinib. In addition, cells resistant to KPT-330 retain their ability to respond to available RCC therapeutics suggesting a novel approach for treatment in KPT-330-na{\"i}ve as well as -resistant RCC patients.",
author = "Wettersten, {Hiromi I.} and Yosef Landesman and Sharon Friedlander and Sharon Shacham and Michael Kauffman and Weiss, {Robert H}",
year = "2014",
month = "12",
day = "2",
doi = "10.1371/journal.pone.0113867",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth

AU - Wettersten, Hiromi I.

AU - Landesman, Yosef

AU - Friedlander, Sharon

AU - Shacham, Sharon

AU - Kauffman, Michael

AU - Weiss, Robert H

PY - 2014/12/2

Y1 - 2014/12/2

N2 - Purpose: Despite the advent of FDA-approved therapeutics to a limited number of available targets (kinases and mTOR), PFS of kidney cancer (RCC) has been extended only one to two years due to the development of drug resistance. Here, we evaluate a novel therapeutic for RCC which targets the exportin-1 (XPO1) inhibitor. Materials and Methods: RCC cells were treated with the orally available XPO1 inhibitor, KPT-330, and cell viability and Annexin V (apoptosis) assays, and cell cycle analyses were performed to evaluate the efficacy of KPT-330 in two RCC cell lines. Immunoblotting and immunofluorescence analysis were performed to validate mechanisms of XPO1 inhibition. The efficacy and on-target effects of KPT-330 were further analyzed in vivo in RCC xenograft mice, and KPT-330-resistant cells were established to evaluate potential mechanisms of KPT-330 resistance. Results: KPT-330 attenuated RCC viability through growth inhibition and apoptosis induction both in vitro and in vivo, a process in which increased nuclear localization of p21 by XPO1 inhibition played a major role. In addition, KPT-330 resistant cells remained sensitive to the currently approved for RCC multi-kinase inhibitors (sunitinib, sorafenib) and mTOR inhibitors (everolimus, temsirolimus), suggesting that these targeted therapeutics would remain useful as second line therapeutics following KPT-330 treatment. Conclusion: The orally-available XPO1 inhibitor, KPT-330, represents a novel target forRCC whose in vivo efficacy approaches that of sunitinib. In addition, cells resistant to KPT-330 retain their ability to respond to available RCC therapeutics suggesting a novel approach for treatment in KPT-330-naïve as well as -resistant RCC patients.

AB - Purpose: Despite the advent of FDA-approved therapeutics to a limited number of available targets (kinases and mTOR), PFS of kidney cancer (RCC) has been extended only one to two years due to the development of drug resistance. Here, we evaluate a novel therapeutic for RCC which targets the exportin-1 (XPO1) inhibitor. Materials and Methods: RCC cells were treated with the orally available XPO1 inhibitor, KPT-330, and cell viability and Annexin V (apoptosis) assays, and cell cycle analyses were performed to evaluate the efficacy of KPT-330 in two RCC cell lines. Immunoblotting and immunofluorescence analysis were performed to validate mechanisms of XPO1 inhibition. The efficacy and on-target effects of KPT-330 were further analyzed in vivo in RCC xenograft mice, and KPT-330-resistant cells were established to evaluate potential mechanisms of KPT-330 resistance. Results: KPT-330 attenuated RCC viability through growth inhibition and apoptosis induction both in vitro and in vivo, a process in which increased nuclear localization of p21 by XPO1 inhibition played a major role. In addition, KPT-330 resistant cells remained sensitive to the currently approved for RCC multi-kinase inhibitors (sunitinib, sorafenib) and mTOR inhibitors (everolimus, temsirolimus), suggesting that these targeted therapeutics would remain useful as second line therapeutics following KPT-330 treatment. Conclusion: The orally-available XPO1 inhibitor, KPT-330, represents a novel target forRCC whose in vivo efficacy approaches that of sunitinib. In addition, cells resistant to KPT-330 retain their ability to respond to available RCC therapeutics suggesting a novel approach for treatment in KPT-330-naïve as well as -resistant RCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84914694787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914694787&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0113867

DO - 10.1371/journal.pone.0113867

M3 - Article

C2 - 25461627

AN - SCOPUS:84914694787

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e113867

ER -